Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Idarubicin in Older Patients With Untreated AML or High-Risk MDS
NCT01141725Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Response at 6 months, Incidence of Greater Than or Equal to Grade 3 Toxicity and 2 more. Started Sep 2010; status: completed.
02
Drugs
bendamustine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01141725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141725.